Trump Admin Moves Medical Cannabis to Schedule III

In a decisive move that marks the most significant alteration in federal drug policy since the 1970s, the Trump administration has officially reclassified state-licensed medical marijuana and FDA-approved cannabis products from Schedule I to Schedule III under the Controlled Substances Act. This action, spearheaded by Acting Attorney General Todd Blanche, delivers on the directives outlined…

Read More

New ABCD Study Links Teen Cannabis Use to Cognitive Decline

New research published today in the journal Neuropsychopharmacology has provided perhaps the most robust evidence to date regarding the impact of cannabis on the developing adolescent brain. The study, which analyzed data from more than 11,000 participants in the National Institutes of Health’s (NIH) Adolescent Brain Cognitive Development (ABCD) Study, found a clear correlation between…

Read More

Planet 13 Launches Precision 1:1:1 Cannabis Chocolates in FL

Planet 13 Holdings has officially launched its new Dreamland Chocolate line across its Florida dispensary network as of April 17, 2026. This move introduces a sophisticated suite of cannabinoid-infused confections to the state’s medical cannabis market, specifically highlighting a 1:1:1 THC:CBD:CBN formulation. By focusing on balanced, ratio-driven products rather than simple THC potency, Planet 13…

Read More

Missouri Unveils Regulatory Framework for Cannabis Research

The Missouri Department of Health and Senior Services (DHSS) has officially initiated a pivotal step in the state’s cannabis evolution, filing proposed rules to establish dedicated marijuana research facilities. This development, outlined in the recently introduced 19 CSR 100-1.200, signals a move beyond mere retail and cultivation, aiming to cement Missouri’s position as a hub…

Read More